

OA-GE-12

EFFECT OF WEIGHT LOSS ON PHYSICAL FUNCTION MEASURED BY THE 6-MINUTE WALKING DISTANCE TEST IN INDIVIDUALS WITH OBESITY: RESULTS FROM THE SCALE IBT TRIAL OF LIRAGLUTIDE 3.0 mg

<https://doi.org/10.15605/jafes.034.02.S74>

Cyrus Pasamba and **Mercerose Puno**
Novo Nordisk Pharmaceuticals (Philippines), Inc.

INTRODUCTION

The SCALE IBT trial (NCT02963935) was a 56-week, randomized, double-blind, US-based multicenter trial of liraglutide 3.0 mg vs placebo, with intensive behavior therapy (IBT) (i.e., reduced calorie intake, increased physical activity [max target: 250 min/week], and 23 counseling) in both arms. The secondary endpoint was the change in 6-minute walking distance (6MWD), a test for walking capacity measured by total distance walked along a 20-m marked walkway over 6 minutes.

METHODOLOGY

For the trial, individuals aged ≥ 18 y with a BMI ≥ 30 kg/m² and without diabetes were randomized 1:1 to IBT plus liraglutide 3.0 mg or placebo. The change in body weight and 6MWD from baseline to week 56 was calculated using ANCOVA. Linear regression was used for the correlation analysis of the association between 6MWD and BMI. There were 282 randomized individuals in the full analysis set (47 y, 17% male, BMI 39 kg/m²).

RESULTS

At 56 weeks, mean weight loss was 7.5% with liraglutide 3.0 mg and 4.0% with placebo, estimated treatment difference (ETD [95% CI] 3.5% [1.6, 5.3]; $p=0.0003$). Improvement in 6MWD was 49.5 m vs. 46.4 m, from a mean baseline of 439 m (ETD [95% CI] 3.1 [-12.7, 18.9]; $p=0.70$). Linear regression of baseline 6MWD vs. baseline BMI showed that on average an individual with a BMI that was 1 kg/m² lower compared to another individual was able to walk 4.9 m longer in 6 minutes (slope [95% CI] -4.9 m/(kg/m²) [-6.2, -3.6]; $p<0.0001$).

CONCLUSION

This *post-hoc* analysis showed that greater weight loss was associated with greater improvements in 6MWD in a linear manner, indicating gains in walking capacity.

KEY WORDS

liraglutide, scale, IBT

OA-GE-13

WEIGHT LOSS WITH LIRAGLUTIDE 3.0 mg VERSUS PLACEBO FOR INDIVIDUALS WHO ADHERE TO THE TRIAL DRUG: A SECONDARY ANALYSIS FROM SCALE IBT

<https://doi.org/10.15605/jafes.034.02.S75>

Jena Shaw Tronieri,¹ **Thomas Wadden**,¹ **Danny Sugimoto**,² **Michael T Lund**,³ **Pernille Auerbach**,³ **Lars Endahl**,³ **Domenica Rubino**,⁴ **Cyrus Pasamba**⁵

¹Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

²Cedar Crosse Research Center, Chicago, IL, USA

³Novo Nordisk A/S, Søborg, Denmark

⁴Washington Center for Weight Management and Research, Arlington, VA, USA

⁵Novo Nordisk Pharmaceuticals (Philippines), Inc.

INTRODUCTION

The objective of the SCALE IBT trial was to compare the weight loss of liraglutide 3.0 mg to placebo, both in combination with 56 weeks of intensive behavior therapy (IBT). The primary outcomes of the study were assessed in the intention-to-treat sample, regardless of individuals' medication adherence. The weight loss estimated in the primary analysis, regardless of drug adherence, was 7.5% versus 4.0% for liraglutide 3.0 mg and placebo, respectively, reflecting a treatment difference favoring liraglutide 3.0 mg of 3.5% (95% CI: 1.6%; 5.3%; $p=0.0003$). In this pre-specified secondary analysis, we sought to determine the expected effect of liraglutide 3.0 mg on weight loss, as compared to placebo, if all randomized individuals had adhered to study drug for 56 weeks.

METHODOLOGY

A total of 282 individuals with obesity (BMI ≥ 30 kg/m²) were randomized in a 1:1 ratio to 56 weeks of IBT combined with daily injections of either liraglutide 3.0 mg or placebo. The weight loss, based on the assumption that all individuals adhered to the medication, was estimated using two different approaches. The first approach (mixed model repeated measures; MMRM) estimated the weight loss that would have been achieved if all individuals adhered to the trial drug by utilizing information from individuals still on drug after the point of a given individual's discontinuation to provide a (counter-factual) weight change as if the individual in question had not discontinued the drug. The second (covariate) approach used a regression model to calculate the weight change of individuals with full adherence to trial drug by including adherence as a moderator of the effect of treatment condition on weight change.

RESULTS AND DISCUSSION

The MMRM approach yielded a weight loss difference of 4.6% (95% CI: 2.6%; 6.5%; $p < 0.0001$), and the covariate approach yielded a weight loss difference of 4.6% (95% CI: 2.8%; 6.5%; $p < 0.0001$), with both estimates favoring liraglutide 3.0 mg.

CONCLUSION

The estimated placebo-subtracted weight loss for liraglutide at week 56 of approximately 4.6% in medication-adherent individuals therefore indicates that underlying assumptions are robust. We believe this finding is an important supplement to the study's primary outcome and can inform practitioners' expectations when prescribing liraglutide 3.0 mg in combination with IBT for 56 weeks.

KEY WORDS

liraglutide, obesity, weight loss, scale-IBT

OA-GE-14

EARLY RESPONDERS TO LIRAGLUTIDE 3.0 mg AS ADJUNCT TO DIET+EXERCISE FROM THE SCALE MAINTENANCE TRIAL

<https://doi.org/10.15605/jafes.034.02.S76>

Louis Aronne,¹ Boris Stevenin,² Cecilie Jepsen,³ Sean Wharton,⁴ Ahsan Shoeb⁵

¹Weill Cornell Medicine, New York, NY, USA

²Novo Nordisk Inc, Plainsboro, NJ, USA

³Novo Nordisk, Søborg, Denmark

⁴Wharton Medical Clinic, Weight and Diabetes Management, Hamilton, Canada

⁵Novo Nordisk Pharmaceuticals (Philippines), Inc.

INTRODUCTION

The SCALE Maintenance trial randomized adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) + comorbidities who lost $\geq 5\%$ of initial body weight (BW) during a 4–12-week low calorie diet (1200–1400 kcal/day) run-in period (mean weight loss [WL]: 6.0%) prior to randomization to liraglutide 3.0 mg or placebo as an adjunct to diet and exercise.

METHODOLOGY

This *post-hoc* analysis of SCALE Maintenance compared outcomes in liraglutide 3.0 mg early responders vs. early non-responders (definition: ERs vs. ENRs; $\geq 4\%$ vs. $< 4\%$ WL at week 16 post-randomization). Efficacy outcomes are observed means or proportions for those completing 56 weeks' treatment. The safety analysis set is used for adverse events (AEs).

RESULTS AND DISCUSSION

Mean characteristics at randomization (n=212) for liraglutide 3.0 mg were: 46 years old, 84% female, BMI 36 kg/m². Of those completing 56 weeks' treatment, (n=159); 118 (74.2%) were ERs to liraglutide 3.0 mg and 41 (25.8%) ENRs. At week 56, mean WL was -9.2% in ERs vs. +0.3% in ENRs in addition to run-in WL. 89.8% of ERs maintained run-in weight loss (or lost further weight) during 56 weeks vs. 41.5% of ENRs. The percentage of those who regained all run-in WL by week 56 was 0.0% for ERs vs. 4.9% for ENRs. Percent achieving $\geq 5\%$, $> 10\%$ or $> 15\%$ WL at week 56 was 66.9%, 43.2% and 18.6% for ERs vs. 14.6%, 0.0%, and 0.0% for ENRs. ERs had greater change in mean waist circumference: -7.3 cm vs. +0.3 cm in ENRs. Changes in systolic/diastolic blood pressure were -0.2/+1.9 mmHg in ERs vs. -0.3/+1.6 mmHg in ENRs. Changes in HbA_{1c} in ERs and ENRs were: -0.2% and -0.1% and fasting plasma glucose: -0.5 and -0.6 mmol/L. ERs with AEs was 91.2% vs. 94.3% for ENRs. Serious AEs were 4.4% vs. 0.0% and gastrointestinal AEs 78.1% vs. 60.4% for ERs vs. ENRs, respectively.

CONCLUSION

Among those who completed 56 weeks' treatment on liraglutide 3.0 mg, a greater additional WL of -9.2% was observed for ERs vs. +0.3% for ENRs, with a similar proportion experiencing AEs.

KEY WORDS

scale-maintenance, liraglutide, early responders, obesity